PMID- 32145586
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20211204
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 126
DP  - 2020 Jun
TI  - Dendritic cell vaccine for the effective immunotherapy of breast cancer.
PG  - 110046
LID - S0753-3322(20)30237-7 [pii]
LID - 10.1016/j.biopha.2020.110046 [doi]
AB  - Cancer vaccine is widely considered as a powerful tool in immunotherapy. In 
      particular, the effective antigen processing and presentation natures of 
      dendritic cell (DC) have made it a promising target for the development of 
      therapeutic vaccine for cancer treatment. Here in our study, a versatile cancer 
      cell membrane (CCM) coated calcium carbonate (CC) nanoparticles (MC) that capable 
      of generating in situ tumor-associated antigens (TAAs) for DC vaccination is 
      developed. Low-dose doxorubicin hydrochloride (Dox) could be encapsulated in the 
      CC core of MC to trigger immunogenic cell death (ICD) while chlorins e6 (Ce6), a 
      commonly adopted photosensitizer, was loaded in the CCM of MC for effective 
      photodynamic therapy (PDT) through the generation of reactive oxygen species 
      (ROS) to finally construct the vaccine (MC/Dox/Ce6). Most importantly, our 
      in-depth study revealed the treatment of MC/Dox/Ce6 was able to elicit TAAs 
      population and DC recruitment, triggering the following immune response cascade. 
      In particular, the recruited DC cells could be stimulated in situ for effective 
      vaccinations. Both in vitro and in vivo experiments suggested the capability of 
      this all-in-one DDS to enhance DCs maturation to finally result in effective 
      inhibition of both primary and distant growth of breast cancer upon single 
      administration of low dose Dox and Ce6.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Ni, Jiang
AU  - Ni J
AD  - Department of Pharmacy, The Affiliated Hospital of Jiangnan University (Original 
      Area of Wuxi Third People's Hospital), China.
FAU - Song, Jinfang
AU  - Song J
AD  - Department of Pharmacy, The Affiliated Hospital of Jiangnan University (Original 
      Area of Wuxi Third People's Hospital), China.
FAU - Wang, Bei
AU  - Wang B
AD  - Department of Pharmacy, The Affiliated Hospital of Jiangnan University (Original 
      Area of Wuxi Third People's Hospital), China.
FAU - Hua, Haiying
AU  - Hua H
AD  - Department of Pharmacy, The Affiliated Hospital of Jiangnan University (Original 
      Area of Wuxi Third People's Hospital), China.
FAU - Zhu, Huanhuan
AU  - Zhu H
AD  - Department of Pharmacy, The Affiliated Hospital of Jiangnan University (Original 
      Area of Wuxi Third People's Hospital), China.
FAU - Guo, Xiaoqiang
AU  - Guo X
AD  - Department of Pharmacy, The Affiliated Hospital of Jiangnan University (Original 
      Area of Wuxi Third People's Hospital), China.
FAU - Xiong, Shuming
AU  - Xiong S
AD  - Department of Pharmacy, The Affiliated Hospital of Jiangnan University (Original 
      Area of Wuxi Third People's Hospital), China.
FAU - Zhao, Yiqing
AU  - Zhao Y
AD  - Department of Pharmacy, The Affiliated Hospital of Jiangnan University (Original 
      Area of Wuxi Third People's Hospital), China. Electronic address: 
      zhaoyq6969@126.com.
LA  - eng
PT  - Journal Article
DEP - 20200304
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Chlorophyllides)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
RN  - 5S2CCF3T1Z (phytochlorin)
RN  - 80168379AG (Doxorubicin)
RN  - H0G9379FGK (Calcium Carbonate)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/pharmacology
MH  - Antigens, Neoplasm/*immunology
MH  - Calcium Carbonate/chemistry
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects/immunology
MH  - Chlorophyllides
MH  - Dendritic Cells/*immunology
MH  - Doxorubicin/pharmacology
MH  - Female
MH  - Immunotherapy/*methods
MH  - Mammary Neoplasms, Experimental/immunology/pathology/*therapy
MH  - Mice, Inbred C57BL
MH  - Nanoparticles/chemistry
MH  - Photochemotherapy/*methods
MH  - Photosensitizing Agents/pharmacology
MH  - Porphyrins/pharmacology
MH  - T-Lymphocytes/immunology
OTO - NOTNLM
OT  - Breast cancer
OT  - Calcium carbonate
OT  - Cancer cell membrane
OT  - Ce6
OT  - Dendritic cell vaccine
OT  - Dox
COIS- Declaration of Competing Interest The authors declare that they have no competing 
      interests.
EDAT- 2020/03/08 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/03/08 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/02/21 00:00 [revised]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/03/08 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PHST- 2020/03/08 06:00 [entrez]
AID - S0753-3322(20)30237-7 [pii]
AID - 10.1016/j.biopha.2020.110046 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2020 Jun;126:110046. doi: 10.1016/j.biopha.2020.110046. Epub 
      2020 Mar 4.